Investing

Cymabay Therapeutics Inc : CBAY

CBAY

Stock Data

$32.48

$0.00 (0.00%)

Asset Type

N/A

Exchange

N/A

Currency

N/A

Country

N/A

Sector

N/A

Industry

N/A

Cymabay Therapeutics Inc is a biopharmaceutical company in the clinical stage, dedicated to developing therapies aimed at liver and chronic diseases. Its flagship product, seladelpar, targets primary biliary cholangitis, a liver disease, through a specific receptor activation. Additionally, Cymabay is working on a treatment for type 1 diabetes. Originally known as Metabolex, Inc., the company was founded in 1988 and is based in Fremont, California.

All CBAY Articles

6 Articles

Lee Jackson | Aug 15, 2023 at 8:47 AM EDT

Tuesday’s Top Wall Street Analyst Upgrades and Downgrades: Amgen, Coterra Energy, Eaton, Marriott, Monster Beverage, Mosaic, Urban Outfitters, Wayfair and More

Tuesday's top analyst upgrades and downgrades included Amgen, CF Industries, Coterra Energy, CymaBay Therapeutics, Eaton, Marriott, Monster Beverage, Mosaic, Nutrien,…

Lee Jackson | Mar 10, 2023 at 8:39 AM EST

Friday’s Top Analyst Upgrades and Downgrades: AMD, Etsy, Meta Platforms, Salesforce, Sysco, Teladoc Health and More

Friday's top analyst upgrades and downgrades included Advanced Micro Devices, Asana, Etsy, Exact Sciences, Guardant Health, Hilton Worldwide, Meta Platforms,…

Lee Jackson | Mar 8, 2023 at 8:40 AM EST

Wednesday’s Top Analyst Upgrades and Downgrades: Boeing, Coinbase, Costco, Merck, Regions Financial, Wayfair and More

Wednesday's top analyst upgrades and downgrades included Bluebird Bio, Boeing, Coinbase Global, Costco Wholesale, Envista, Merck, New Fortress Energy, NexTier…

Lee Jackson | Aug 15, 2020 at 6:35 AM EDT

5 Red-Hot Biotech and Medtech Stocks Under $10 With Massive Upside Potential

These are five biotech and medtech stocks for very aggressive accounts that look to get shares count leverage on companies…

Chris Lange | Aug 3, 2020 at 12:03 PM EDT

CymaBay Pulls Off Another Win With PBC Liver Disease Study

CymaBay Therapeutics posted a huge gain to start off the week after the company reported results from a late-stage clinical…

Chris Lange | May 12, 2020 at 9:58 AM EDT

What’s Next for CymaBay’s NASH Study

CymaBay Therapeutics shares more than doubled on Tuesday after the company announced its first-quarter results, along with a corporate update.